Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Intravenous injection of immunoglobulin (IVIG), a mainstay treatment for patients with antibody deficiency, has also proved to have anti-inflammatory effects in autoimmune patients. In their Perspective, Lin and Kinet explain new work (Samuelsson et al.) that provides a mechanism for the anti-inflammatory effect of IVIG.
The authors are in the Division of Allergy and Immunology, Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston MA 02215, USA. E-mail: jkinet{at}caregroup.harvard.edu
The editors suggest the following Related Resources on Science sites:
In Science Magazine
REPORTS
Astrid Samuelsson, Terri L. Towers, and Jeffrey V. Ravetch (19 January 2001) Science291 (5503), 484.
[DOI: 10.1126/science.291.5503.484] |Abstract »|Full Text »|PDF »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Intravenous immunoglobulin does not increase Fc{gamma}RIIB expression on monocytes/macrophages during acute Kawasaki disease.
T. Ichiyama, Y. Ueno, M. Hasegawa, Y. Ishikawa, T. Matsubara, and S. Furukawa (2005)
Rheumatology
44, 314-317
|Abstract »|Full Text »|PDF »
Neonatal lupus syndromes.
J P Buyon, A Rupel, and R M Clancy (2004)
Lupus
13, 705-712
|Abstract »|PDF »
Targeting of platelet integrin {alpha}IIb{beta}3 determines systemic reaction and bleeding in murine thrombocytopenia regulated by activating and inhibitory Fc{gamma}R.
B. Nieswandt, W. Bergmeier, V. Schulte, T. Takai, U. Baumann, R. E. Schmidt, H. Zirngibl, W. Bloch, and J. E. Gessner (2003)
Int. Immunol.
15, 341-349
|Abstract »|Full Text »|PDF »
